IFL (chemotherapy)
| IFL | |
|---|---|
| Specialty | oncology |
IFL is a chemotherapy regimen for treatment of certain cancers, consisting of concurrent treatment with irinotecan, leucovorin (folinic acid), and fluorouracil.[1]
It is similar to the FOLFIRI regimen and uses the same drugs. However, the fluorouracil component is given as a bolus injection rather than as an infusion over 48 hours.[1]
See also[]
References[]
- ^ a b Chen, K; Gong, Y; Zhang, Q; Shen, Y; Zhou, T (2016). "Efficacy and safety of addition of bevacizumab to FOLFIRI or irinotecan/bolus 5-FU/LV (IFL) in patients with metastatic colorectal cancer: A meta-analysis". Medicine. 95 (46): e5221. doi:10.1097/MD.0000000000005221. PMC 5120901. PMID 27861344.
 | This antineoplastic or immunomodulatory drug article is a stub. You can help Wikipedia by . |
Categories:
- Chemotherapy regimens used in colorectal cancer
- Antineoplastic and immunomodulating drug stubs